Vaxcyte Inc

Company Profile

Vaxcyte Inc had its IPO on 2020-06-12 under the ticker symbol PCVX.

The company operates in the Healthcare sector and Biotechnology industry. Vaxcyte Inc has a staff strength of 158 employees.

Stock update

Shares of Vaxcyte Inc opened at $52.08 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $51.87 - $53.39, and closed at $51.92.

This is a -0.95% slip from the previous day's closing price.

A total volume of 470,680 shares were traded at the close of the day’s session.

In the last one week, shares of Vaxcyte Inc have slipped by -2.22%.

Vaxcyte Inc's Key Ratios

Vaxcyte Inc has a market cap of $4.98 billion, indicating a price to book ratio of 10.0497 and a price to sales ratio of 0.

In the last 12-months Vaxcyte Inc’s revenue was $0 with a gross profit of $-22995000 and an EBITDA of $-300639008. The EBITDA ratio measures Vaxcyte Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Vaxcyte Inc’s operating margin was 0% while its return on assets stood at -19.82% with a return of equity of -29.42%.

In Q2, Vaxcyte Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Vaxcyte Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-3.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vaxcyte Inc’s profitability.

Vaxcyte Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -19.7025. Its price to sales ratio in the trailing 12-months stood at 0.

Vaxcyte Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.50 billion

Total Liabilities

$60.22 million

Operating Cash Flow

$0

Capital Expenditure

$2.14 million

Dividend Payout Ratio

0%

Vaxcyte Inc ended 2024 with $1.50 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.50 billion while shareholder equity stood at $1.43 billion.

Vaxcyte Inc ended 2024 with $0 in deferred long-term liabilities, $60.22 million in other current liabilities, 97000.00 in common stock, $-650927000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $531.03 million and cash and short-term investments were $1.29 billion. The company’s total short-term debt was $5,986,000 while long-term debt stood at $0.

Vaxcyte Inc’s total current assets stands at $1.31 billion while long-term investments were $153.73 million and short-term investments were $756.03 million. Its net receivables were $0 compared to accounts payable of $16.27 million and inventory worth $0.

In 2024, Vaxcyte Inc's operating cash flow was $0 while its capital expenditure stood at $2.14 million.

Comparatively, Vaxcyte Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$51.92

52-Week High

$54.97

52-Week Low

$20.49

Analyst Target Price

$66.14

Vaxcyte Inc stock is currently trading at $51.92 per share. It touched a 52-week high of $54.97 and a 52-week low of $54.97. Analysts tracking the stock have a 12-month average target price of $66.14.

Its 50-day moving average was $48.84 and 200-day moving average was $45.92 The short ratio stood at 16.85 indicating a short percent outstanding of 0%.

Around 343.7% of the company’s stock are held by insiders while 9232.9% are held by institutions.